.jpeg)
2026-07-23 02:50:52
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor for ALK-positive advanced NSCLC with potent ALK inhibition and superior CNS penetration. This article covers its mechanism of action, therapeutic advantages, efficacy factors, and adverse effect management.
2026-07-23 02:29:04
Pemigatinib is an FGFR inhibitor for FGFR2 fusion/rearrangement-positive cholangiocarcinoma. This article covers common adverse effects (hyperphosphatemia, alopecia, stomatitis), ophthalmologic monitoring requirements, and dose modification strategies for safe long-term treatment.
2026-07-23 02:21:07
Selpercatinib is a selective RET kinase inhibitor for RET fusion-positive NSCLC and RET-mutant medullary thyroid carcinoma. This guide addresses meal timing, twice-daily dosing, missed dose management, and key monitoring considerations during treatment.
2026-07-23 02:11:21
Mitotane is the cornerstone drug for adrenocortical carcinoma (ACC) treatment. This article covers initial dosing, target plasma concentration range (14–20 mg/L), monitoring frequency, and adverse effect management for safe and effective therapy.
2026-07-21 07:22:56
A balanced review of leflunomide-related eye symptoms, incidence, monitoring recommendations, and management strategies for rheumatoid arthritis patients.
2026-07-21 07:17:20
A structured overview of progression criteria, molecular profiling, and sequential treatment strategies following resistance to garsorasib in advanced NSCLC.
2026-07-20 07:28:12
Capivasertib is an oral AKT inhibitor with molecular formula C₂₁H₂₅ClN₆O₂, selectively binding to AKT protein to block PI3K/AKT signaling, used in precision therapy for breast cancer and other tumors.
2026-07-20 07:22:46
Capivasertib is an oral AKT inhibitor used to treat breast cancer and prostate cancer. This article compares the original brand and generic versions from Laos, highlighting differences in price, composition, and considerations for selection.
2026-07-17 07:10:28
This article analyzes the 2026 FDA approval of Selumetinib for adult Neurofibromatosis Type 1 (NF1) with symptomatic plexiform neurofibromas (PN). Covering KOMET Phase III data, BSA-based dosing, hepatic impairment adjustments, and global market availability, it serves as a comprehensive guide for clinicians.
2026-07-16 07:37:00
This guide details the essential baseline evaluations and proactive management strategies for patients starting Lenvatinib therapy. It covers hypertension, proteinuria, hypothyroidism, hand-foot skin reactions, cardiac monitoring, and drug interactions.
2026-07-15 07:25:49
This guide provides global patients with comprehensive information on Inluriyo, covering its active ingredient, mechanism of action, eligible population, dosing guidelines, and safety precautions.
2026-07-14 05:31:14
Idelalisib is an oral PI3Kδ inhibitor indicated for relapsed/refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). The recommended dose is 150 mg twice daily. Close monitoring for severe hepatic, pulmonary, and intestinal toxicities, as well as life-threatening diarrhea, is required. This article covers indications, dosing, warnings, and adverse reactions.
